IMPACT OF AGE ON SURVIVAL OF PATIENTS WITH OVARIAN-CANCER

被引:35
作者
MARKMAN, M
LEWIS, JL
SAIGO, P
HAKES, T
RUBIN, S
JONES, W
REICHMAN, B
CURTIN, J
BARAKAT, R
ALMADRONES, L
MORRISSEY, T
HOSKINS, W
机构
[1] MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,BREAST GYNECOL SERV,NEW YORK,NY 10021
[2] MEM SLOAN KETTERING CANC CTR,DEPT SURG,GYNECOL SERV,NEW YORK,NY 10021
[3] MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021
关键词
D O I
10.1006/gyno.1993.1113
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In an effort to determine if there are significant differences in outcome between elderly (≥65 years of age) and younger (<65 years of age) women with epithelial ovarian cancer we examined the survival of patients with this malignancy who underwent their initial surgical evaluation at the Memorial Sloan-Kettering Cancer Center from January 1987-January 1991. The actuarial median overall survival for the 98 younger patients has not been reached but will exceed 4 years, compared to a median survival of 24 months for the 48 elderly patients (P < 0.0001). For individuals with advanced (stages 3-4) disease, excluding patients with tumors of low malignant potential, the median survival for the younger patient population has also not been reached and will exceed 4 years, compared to 21 months for the older population (P < 0.0001). Even in the limited number of patients with local/regional (stages 1-2) ovarian cancer, there was a statistically significant superior survival for the younger group of patients (P < 0.02). With a single exception, all deaths were believed to be due principally to disease progression, rather than to an unrelated comorbid medical event. We conclude that elderly patients with ovarian cancer experience a significantly inferior survival than younger individuals with this malignancy. Evaluation of larger populations will be required to confirm the results of this analysis and to probe for explanations for the striking survival differences we have observed. © 1993 Academic Press, Inc.
引用
收藏
页码:236 / 239
页数:4
相关论文
共 9 条
  • [1] BARNHILL D, 1985, OBSTET GYNECOL, V65, P53
  • [2] BERCHUCK A, 1990, CANCER RES, V50, P4087
  • [3] DOSE-RESPONSE EFFECT OF ADJUVANT CHEMOTHERAPY IN BREAST-CANCER
    BONADONNA, G
    VALAGUSSA, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1981, 304 (01) : 10 - 15
  • [4] CANCER STATISTICS, 1991
    BORING, CC
    SQUIRES, TS
    TONG, T
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) : 19 - 36
  • [5] GERSHENSON DM, 1990, CANCER, V65, P578, DOI 10.1002/1097-0142(19900201)65:3<578::AID-CNCR2820650332>3.0.CO
  • [6] 2-N
  • [7] HAKES T, 1989, P AN M AM SOC CLIN, V8, P152
  • [8] MARKMAN M, 1993, CANCER, V71, P634
  • [9] STUDIES OF THE HER-2/NEU PROTO-ONCOGENE IN HUMAN-BREAST AND OVARIAN-CANCER
    SLAMON, DJ
    GODOLPHIN, W
    JONES, LA
    HOLT, JA
    WONG, SG
    KEITH, DE
    LEVIN, WJ
    STUART, SG
    UDOVE, J
    ULLRICH, A
    PRESS, MF
    [J]. SCIENCE, 1989, 244 (4905) : 707 - 712